ADMA Biologics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $107,191 | $81,875 | $73,903 | $67,274 |
Gross Profit | 57,311 | 38,915 | 30,898 | 24,652 |
EBITDA | 41,248 | 23,935 | 16,342 | 11,055 |
EBIT | 39,201 | 21,821 | 14,233 | 8,962 |
Net Income | 32,062 | 17,806 | -17,644 | 2,565 |
Net Change In Cash | 107,191 | 81,875 | 73,903 | 67,274 |
Free Cash Flow | 43,281 | -4,580 | 16,188 | 11,228 |
Cash | 88,244 | 45,325 | 51,352 | 74,156 |
Basic Shares | 242,167 | 236,414 | 225,968 | 233,761 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $258,214 | $154,079 | $80,942 | $42,219 |
Gross Profit | 88,217 | 35,265 | 1,173 | -19,071 |
EBITDA | 29,964 | -39,239 | -57,875 | -64,039 |
EBIT | 21,632 | -46,352 | -63,370 | -67,982 |
Net Income | -28,239 | -85,183 | -84,452 | -87,605 |
Net Change In Cash | 258,214 | 154,079 | 80,942 | 42,219 |
Cost of Revenue | 35,432 | -4,832 | 29,169 | |
Free Cash Flow | 3,819 | -73,419 | -125,880 | -114,729 |
Cash | 51,352 | 86,521 | 51,089 | 55,921 |
Basic Shares | 223,977 | 197,874 | 139,578 | 86,145 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.13 |
2024-03-31 | $0.08 |
2023-12-31 | -$0.08 |
2023-09-30 | $0.01 |
